WHO ICTRP trial
A Phase 2/3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone…
NL-OMON54799 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54799 |
|---|---|
| Public title | A Phase 2/3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer |
| Scientific title | A Phase 2/3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer - I3Y-MC-JPCM |
| Primary sponsor | Eli Lilly |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Austria;Belgium;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;Spain;Sweden;United Kingdom |
| Conditions | Metastatic Castration-Resistant Prostate Cancer Prostate Cancer;10038364 |
| Interventions | Study treatment is defined as blinded study drug (abemaciclib or placebo) and/or abiraterone acetate plus prednisone. Abemaciclib, abiraterone acetate, and prednisone are administered orally on Days 1 through 28 of a 28-day cycle. Part 1… |
| Registration date | Oct 30, 2018 |
| Target size | 12 |
| Secondary IDs | 2016-004276-21;NCT03706365;NL67029.028.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: